scholarly journals Cancer registry data based estimation of regional cancer incidence: application to breast and colorectal cancer in French administrative regions

1999 ◽  
Vol 53 (9) ◽  
pp. 558-564 ◽  
Author(s):  
M. Colonna ◽  
P. Grosclaude ◽  
J. Faivre ◽  
A. Revzani ◽  
P. Arveux ◽  
...  
2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Maximilian Richter ◽  
Lena Sonnow ◽  
Amir Mehdizadeh-Shrifi ◽  
Axel Richter ◽  
Rainer Koch ◽  
...  

Abstract Objectives To evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison. Methods Between 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR). Results Relative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001). Conclusions Our findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.


2020 ◽  
Vol 128 (10) ◽  
pp. 107004
Author(s):  
Nathan C. Coleman ◽  
Richard T. Burnett ◽  
Majid Ezzati ◽  
Julian D. Marshall ◽  
Allen L. Robinson ◽  
...  

2011 ◽  
Vol 31 (5) ◽  
pp. 489-500 ◽  
Author(s):  
Minjung Lee ◽  
Kathleen A. Cronin ◽  
Mitchell H. Gail ◽  
Eric J. Feuer

2013 ◽  
Vol 14 (9) ◽  
pp. 5367-5370 ◽  
Author(s):  
Alireza Mosavi-Jarrahi ◽  
Toraj Ahmadi-Jouibari ◽  
Farid Najafi ◽  
Yadollah Mehrabi ◽  
Abbas Aghaei

2019 ◽  
Author(s):  
Ines Mesa-Eguiagaray ◽  
Sarah H Wild ◽  
Philip S. Rosenberg ◽  
Sheila M Bird ◽  
David H Brewster ◽  
...  

AbstractBackgroundStrategies for breast cancer prevention are informed by assessing whether incidence differs by tumour biology. We describe temporal trends of breast cancer incidence by molecular subtypes in Scotland.MethodsPopulation-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age- period- cohort models were used to assess whether significant differences were observed in incidence trends by ER status.ResultsER positive tumour incidence steadily increased particularly for women of screening age 50 to 69 years from 1997 till around 2011 (1.6%/year, 95%CI: 1.2 to 2.1). ER negative incidence decreased among all ages at a consistent rate of −0.7%/year (95%CI: −1.5, 0) from around 2000-2016. Compared to the 1941-1959 central birth cohort, women born 1912-1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born 1960- 1986 had higher IRR for ER- tumours.ConclusionsWe show evidence of aetiologic heterogeneity of breast cancer. Future incidence and survival reporting should be monitored by molecular subtypes.


CHEST Journal ◽  
2020 ◽  
Author(s):  
Lihua Liu ◽  
Jean-Christophe N. Rwigema ◽  
Ziwei Song ◽  
Myles Cockburn ◽  
Albert J. Farias ◽  
...  

2019 ◽  
Vol 18 (5) ◽  
pp. 5-11
Author(s):  
G. V. Petrova ◽  
O. P. Gretsova ◽  
V. V. Starinsky

The purpose of the study was to compare data on the cancer incidence rates for 2016 between the official reports on cancer statistics and federal cancer registry, collected in December 2018.Material and Methods. The study estimated the total data on 18 parameters from 35 regions of Russia, covering 66.3 million people (2016). The database of the Russian cancer registry and the database containing reports on the state cancer statistics were used. The cancer statistics/cancer registry ratio was assessed.Results. No differences in cancer incidence between the official reports on cancer statistics and cancer registry data were found. In the official reports on cancer statistics, the mortality rate, the proportion of posthumously recorded patients per 100 newly diagnosed, the proportion of deaths from diseases not related to cancer per 100 deceased patients, the cancer prevalence and the prevalence rate of unspecified malignant tumors were slightly reduced (to 10 %, 9 %, 5 %, and 4 %, respectively), and the rate of cancer detection, the proportion of histologically verified diagnoses and the proportion of cancers detected in stage III were increased (to 19 %, 10 % and 14 %, respectively) compared to those in cancer registry data.Conclusion. Improvement in the quality and completeness of information about cancer patients is associated rather with increasing the annual report length than with the need to improve the cancer registration system itself.


Sign in / Sign up

Export Citation Format

Share Document